{"entity":{"id":"nct04079166","kind":"trial","name":"SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)","aka":["SCOPE"],"tldr":"A phase 2 trial of SCIB1 or iSCIB1+ DNA vaccine in melanoma, run by Scancell Ltd, active and no longer recruiting.","summary":"SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study) is a phase 2 interventional study registered as NCT04079166 by Scancell Ltd, with 173 participants enrolled, started 2019-08-19 and due to reach its primary completion in 2027-01-31. Interventions recorded: SCIB1 or iSCIB1+ DNA vaccine.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04079166","url":"https://clinicaltrials.gov/study/NCT04079166"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma","advanced-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["scancell"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04079166","phase":"2","setting":"A Phase 2, Multicentre, Open-Label, Umbrella Study of SCIB1 and iSCIB1+ in Patients With Advanced Unresectable Melanoma Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)","sponsor":"Scancell Ltd","started":"2019-08-19","startedType":"actual","enrolled":173,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04079166/","neighbours":{"cancer":[{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/"}],"company":[{"id":"scancell","kind":"company","name":"Scancell","route":"/companies/scancell/"}]}}